Accumulation of Neurocan, a Brain Chondroitin Sulfate Proteoglycan, in Association with the Retinal Vasculature in RCS Rats

Yiqin Zhang,¹ Uwe Rauch,² and Maria-Thereza R. Perez¹

PURPOSE. To examine whether and how the retinal distribution of the chondroitin sulfate proteoglycan neurocan is affected after photoreceptor cell loss and whether it correlates with the multiple secondary cellular changes that accompany the photoreceptor degeneration.

METHODS. Retinas from normal rats (Sprague-Dawley; postnatal days [P]0–P70), RCS rats with dystrophic retinas (P0–P300), RCS-rdy¹ congentic rats with nondystrophic retinas (P0–P202), and rhodopsin mutant rats, P23H (P0–P257) and S334ter (P0–P220), were processed for immunohistochemistry using a polyclonal antibody to rat neurocan.

RESULTS. The overall distribution of neurocan was similar in all retinas examined. Neurocan immunostaining was detected over the nerve fiber layer, the plexiform layers, and the ciliary epithelium. With age, labeling throughout the plexiform layers decreased continuously. In RCS rats however, conspicuous labeling was also seen in association with retinal vessels, from P15 onward.

CONCLUSIONS. Accumulation of neurocan in association with the retinal vasculature does not correlate with photoreceptor cell loss, because it was not observed in the rhodopsin mutant rats. During the earliest stages of the disease, accumulation of debris in the subretinal space in RCS rats may be sufficient per se to initiate a cascade of metabolic changes that result in accumulation of neurocan. With time, the neurocan accumulated perivascularly may, by interaction with other matrix molecules, modulate at least some of the vascular alterations observed in this animal model.

Chondroitin sulfate proteoglycans (CS-PGs) constitute a subclass of proteoglycans consisting of a core protein to which one or more sulfated glycosaminoglycan side chains are covalently attached (see, e.g., Ref. 1). Different core proteins and variations in the size, structure, and degree of sulfation of the glycosaminoglycan chains account for the diversity in CS-PGs that have thus far been identified. These macromolecules are found mostly in cartilage and in the central nervous system as components of the extracellular matrix and also in association with cell membranes.¹ Whereas in cartilage, aggregates of highly hydrated proteoglycans are primarily responsible for the physical properties of this tissue, their function in the central nervous system is elusive. In the latter, CS-PGs are mainly expressed during development and in response to injury, both situations characterized by high plasticity of the tissue.²

In the retina, biochemical and cytotoxic methods also reveal the presence of structurally distinct CS-PGs and it appears that photoreceptor cells, inner retinal neurons, retinal glial cells, and the retinal pigment epithelium (RPE) are capable of synthesizing these molecules. Accordingly, CS-PGs have been localized in the interphotoreceptor matrix, in the synaptic layers, in the nerve fiber layer, and at the level of the inner limiting membrane.³⁻¹¹ As in other tissues, retinal proteoglycans seem to play a role, not only in the development and functioning of the normal retina, but also in pathologic processes. Alterations of the structure and chemical composition of the interphotoreceptor matrix have been observed in animal models of retinitis pigmentosa (RP), and occur both when the defect lies in the photoreceptors themselves and when the RPE is defective.

Most changes are likely to occur secondary to photoreceptor cell degeneration, but have in some instances also preceded the degeneration, suggesting that alterations in the distribution of proteoglycans may in part contribute to the cell loss.¹⁵⁻¹⁸ Proteoglycan levels are also likely to play a role in the secondary pathology that is observed in the retinas of animal models and of patients with RP. A number of cellular changes are noted after photoreceptor cell degeneration, such as loss of other neuronal cells, activation of glial cells, sprouting of neurites, and vascular degeneration and proliferation.¹⁹⁻²² All these changes involve dynamic cell–cell and cell–matrix interactions and are therefore also likely to be preceded and/or accompanied by alterations in the levels of proteoglycans and of their receptors/ligands.

The purpose of the present study was to examine the distribution of the CS-PG neurocan in dystrophic rat retinas. Neurocan, a member of the lectican family of hyaluronan-binding proteoglycans is one of the most abundant PGs in developing brain tissue, and its structure and interactions point to a role in the organization of the matrix and in the modulation of normal developmental processes.²³⁻²⁵ Neurocan has been detected in the innermost retinal layers in embryonic rat retinas and in the plexiform layers during the first postnatal weeks.³⁻⁵,₁⁵⁻⁻²² However, reexpression of neurocan has been reported in adult rats after transient retinal ischemia,²⁶ concomitant with other reports showing that the expression of this CS-PG is upregulated after nerve tissue injury.²⁹⁻³¹

Using immunocytochemistry, we thus examined the distribution of neurocan in retinas of Royal College of Surgeons (RCS) rats and of P23H and S334ter transgenic rats. In RCS rats, a mutation in the gene encoding the receptor tyrosine kinase
MERTK,3,2 results in defective phagocytosis of shed rod outer segment disc membranes by the RPE, ultimately leading to photoreceptor cell degeneration,3,34. As the disease progresses, the entire retina is affected and ganglion cell loss, activation of glial cells, neovascularization of the RPE, and formation of vitreoretinal membranes are also observed.3,2,35–38

In P23H and S334ter rats, degeneration results from rhodopsin mutations and, as such, is a primary photoreceptor event,39,40 as opposed to the situation in RCS rats. Vascular changes have been previously observed in other models of retinal degeneration, including a P23H transgenic mouse,41–43 and alterations in proteoglycan levels can therefore be expected.

MATERIALS AND METHODS

Experimental Animals

The experiments were conducted with the approval of the local animal experimentation ethics committee. Animals were handled according to the guidelines on care and use of experimental animals set by the Government Committee on Animal Experimentation at the University of Lund and the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. The animals examined included Sprague-Dawley rats, postnatal days (P)9 to P70, (n = 30), RCS-rdy− rats with nondystrophic retinas (P0–P202, n = 12), RCS rats with dystrophic retinas (pink-eyed, tan-haired, P0–P300, n = 59), P23H rats (line 1; P0–P257, n = 35), and S334ter rats (line 4; P0–P220, n = 24). Homozygous breeders of P23H and S334ter rats were produced by Chrysalis DNX Transgenic Sciences (Princeton, NJ), and developed and provided by Mathew M. LaVail (University of California, San Francisco, CA). Analysis was performed on heterozygous animals obtained by mating with wild-type Sprague-Dawley rats. All animals were maintained on a 12-hour light-dark cycle. The younger animals were killed by decapitation, and older animals were anesthetized with carbon dioxide before decapitation.

Tissue Preparation

Eyes were quickly enucleated and immersed in a freshly prepared solution of 4% formaldehyde in Sörensen buffer (0.1 mM, pH 7.2). Small eyes were kept in fixative for 2 hours. In larger eyes, the anterior segment, lens, and vitreous bodies were removed 10 minutes after immersion in fixative. The posterior segments were transferred to fresh fixation medium (as just described) and kept at 4°C for two additional hours. The tissue was subsequently rinsed and cryoprotected in Sörensen buffer containing sucrose. The tissue was embedded in an albumin-glycerin medium (30 g egg albumin, 3 g gelatin, 100 ml distilled water) and frozen. Sections were obtained on a cryostat (12 µm), collected on gelatin-chrome-alum-coated slides, air dried, and stored at −20°C until used. A few of the sections processed for neurocan immunoreactivity were photographed and subsequently counterstained with hematoxylin and eosin. After fixation and cryoprotection, some retinas were instead dissected from the RPE and mounted with the vitreous side up on glass slides.

Antibodies

Antibodies included neurocan, a polyclonal antiserum, raised in rabbits immunized with immunoaffinity-purified rat neurocan and boosted with recombinant rat neurocan produced in mammalian cells44–45; RECA, a mouse anti-rat RECA-1 antigen, which recognizes a cell surface antigen distributed on all vascular endothelium (Serotec, Oxford, UK); and cytokeratin, a monoclonal mouse anti-human cytokeratin (MNF-116; Dako, Glostrup, Denmark).

Immunocytochemistry

Cryostat sections and wholemounted retinas were incubated for 90 minutes with 0.1 mM PBS containing 1% BSA, 0.25% Triton X-100 (PBTx), and 5% normal serum, followed by overnight incubation at 4°C with rabbit anti-neurocan serum (1:1000 in PBTx containing normal serum). For colocalization studies, primary antibodies were applied in combination (neurocan, 1:1000; RECA-1, 1:100; cytokeratin, 1:40). After they were rinsed, sections were incubated for 90 minutes with Texas red sulfonyl chloride-conjugated donkey anti-rabbit (1:100; Jackson ImmunoResearch, West Grove, PA) and/or fluorescein isothiocyanate-conjugated goat anti-mouse. After they were immunostained, sections were rinsed and mounted with buffered glycerol containing the antifade agent phenylenediamine (Merck, Darmstadt, Germany). To verify the specificity of the neurocan labeling, the diluted neurocan antiserum was preincubated with affinity-purified neurocan for 24 hours before application to the sections, and the neurocan antiserum was excluded from the incubation. Sections were viewed with a light microscope equipped for fluorescence microscopy, and micrographs were taken with a digital camera. The images were processed with Photoshop (Adobe, San Jose, CA).

Western Blot Analysis

Frozen (−80°C) pieces of retinal or brain tissue of 8-day-old (P8) or adult rats (P60) were homogenized in TBS buffer containing protease inhibitors. After adjustment of the protein concentrations, extracts were partially treated with chondroitinase-avdibiontin complex (ABC). The extracted proteins were separated by 5% SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes (Hybond-P; Amersham, Uppsala, Sweden). The membranes were incubated with the polyclonal antibody against neurocan and developed with horseradish peroxidase–conjugated secondary antibody, with an enhanced chemiluminescence detection system ((ECL+; Amersham).

RESULTS

Immunocytochemistry

Between P0 (day of birth) and P12, differences in the accumulation of neurocan were observed between the central and peripheral retinas, reflecting a center-to-periphery gradient that appeared to parallel the center-to-periphery maturation of the retina. The same observation was made in normal (illustrated in Figs. 1D–F), RCS, and in transgenic rats. To facilitate comparison, however, the distribution observed in the midperiphery will be given in the subsequent descriptions, unless stated otherwise.

Normal Rats: Sprague-Dawley and RCS Rats with Nondystrophic Retinas

At the ages examined, no differences were noted between the distribution of neurocan in Sprague-Dawley rats and in RCS rats with nondystrophic retinas. Both will therefore be referred to as normal retinas (control subjects) in the present study.

Figure 1 illustrates the distribution of neurocan immunoreactivity in normal retinas. At P0, intense labeling was observed in the posterior part of the optic nerve (Fig. 1A), in the inner retina (Fig. 1B), and in the ciliary epithelium (Fig. 1C). In the retina, intense and diffuse neurocan immunoreactivity was found in the developing inner plexiform layer (IPL; Fig. 1B), and it was possible to discern a number of immunonegative strands in the proximal neuroblastic layer, next to the IPL. No major differences were noted at P5, except that a discrete sublayering was observed in the IPL and more diffuse labeling was seen in the inner two thirds of the neuroblastic layer (Figs. 1D, 1E). At P5, a localized labeling was observed within the developing inner nuclear layer (INL; Fig. 1G). Figure 1H shows the same section as in 1G, which was counterstained after being immunoprocessed and photographed. The accumulation of neurocan labeling occurred in a region where no cell bodies were noted, delineating a more proximal region within the INL.
that exhibited rounder cell bodies, and a distal region where the cell bodies were more tightly packed and where most still exhibited an oval shape (Fig 1H). At this time point, weak labeling was also seen in the nerve fiber layer (NFL; Fig. 1G) and as a thin line in the subretinal space (not shown).

By P12, staining in the retina was almost completely restricted to the IPL, the NFL, and the region corresponding to the photoreceptor outer segments (Fig. 1I). Between P12 and P70, no significant differences in the distribution of immunolabeling were noted, but whereas immunoreactivity throughout the ciliary epithelium, the posterior region of the optic nerve, the photoreceptor outer segments, and the NFL remained intense, labeling in the IPL gradually decreased with age (Figs. 1J, 1K).

Neurocan staining was also observed on rare occasions in association with a large superficial retinal vessel (not shown).

RCS Rats

Between P0 and P12, the distribution of neurocan immunoreactivity resembled that observed in control retinas, both when compared with RCS nondystrophic retinas and with retinas of Sprague-Dawley rats. This distribution is illustrated in Figures 2A and 2B, which show neurocan in the midperiphery of RCS rat retinas at P0 and P12, respectively. Labeling throughout the plexiform layers, the NFL, and the ciliary epithelium was also comparable to that of normal retinas at all ages examined.

At P15, however, distinct labeling was observed in association with several large superficial blood vessels at the level of the optic nerve head (Fig. 2C). With increasing age, this type of labeling was seen in all retinal eccentricities (Fig. 2H). Staining was also present at P35 and onward, coinciding with vascular profiles at the level of the outer plexiform layer (OPL), with vessels running between the vitreous retinal surface and the OPL, and vessels running along with the nerve fiber bundles (Figs. 2D-1). Figure 2E depicts the same section as Figure 2D, which was counterstained after being immunoprocessed and photographed, and shows that the accumulation of neurocan labeling across the IPL and INL coincided with a vascular profile. In older animals, immunoreactivity was also detected in association with retinal blood vessels reaching the RPE (described later).

Increased neurocan labeling also appeared in areas associated with the debris zone in the subretinal space at all ages examined (Figs. 2F-H).

Colocalization of Neurocan with RECA and Cytokeratin in RCS Retinas

Neurocan and RECA. Retinal tissue obtained from RCS rats with dystrophic retinas (sections and wholemounted retinas) were processed for simultaneous localization of neurocan and rat endothelial cell antigen (RECA). Figures 3A-D show neurocan immunoreactivity associated both with larger RECA-labeled superficial vessels (Fig. 3A) and smaller intraretinal vessels (Figs. 3B-D). It was not possible to establish the exact site of accumulation, but neurocan immunoreactivity appeared to be concentrated around the vessels (Figs. 3A-D).

Neurocan and Cytokeratin. Staining of epithelial cells with anti-cytokeratin resulted in labeling in the position of the RPE at all ages examined. By P75 and onward, cytokeratin labeling was also present at various levels within the retina, and in some sections, cytokeratin and neurocan immunoreactivities were associated with the same vascular profiles (Figs. 3E, 3F).

P23H and S334ter Rats

The overall distribution of neurocan immunostaining in P23H and S334ter rat retinas appeared similar to that seen in control retinas, except for labeling throughout the photoreceptor outer segments, which disappeared as photoreceptor cells were lost. Increased accumulation of neurocan was occasionally noted in older animals at the level of the NFL in association with larger superficial vessels (Fig. 4). However, the incidence of this type of labeling did not seem to be higher than in control retinas. Further, abnormal accumulation of neurocan in association with intraretinal vessels was not observed in these specimens at any of the time points examined: P23H rats (P0–P257), S334ter rats (P0–P220).

Antibody Specificity

In sections incubated with secondary antibodies alone, weak signal was detected throughout the photoreceptor inner and outer segments in normal animals and in the debris zone in the RCS dystrophic rat retinas (not shown). After incubation of sections with the preadsorbed neurocan antiseraum, no specific immunolabeling was detected in the ciliary epithelium, the optic nerve, or the retina of normal rats (Figs. 5A, 5B) or of rats with dystrophic retinas (Figs. 5C, 5D and 5E, 5F). In Western blot analysis, no cross-reactivity of the neurocan antisera with brevican, one of the most closely related molecules, was observed. No staining was detected in brain extracts from neurocan-knockout mice, further confirming the specificity of the antisera.45

Western Blot Analysis

Normal Rats: Sprague-Dawley and RCS Rats with Non-dystrophic Retinas. In 8-day-old rat brain tissue, proteolytically unprocessed neurocan molecules are the predominating form. Chondroitinase ABC treatment converts these molecules (due to the heterogeneous glycosaminoglycan substitution, appearing as a smear well above 250 kDa) to a homogenous core protein appearing with a stronger signal as a well-defined band of 250 kDa. At 150 kDa, the much less abundant core protein of the C-terminal proteolytic fragment is also apparent, whereas the more heterogeneous signal of this fragment in its glycosaminoglycan-substituted form was too dilute to be detected. Similar to brain tissue, after elimination of the glycosaminoglycan modification by chondroitinase ABC, a core protein of 250 kDa corresponding to the unprocessed neurocan molecule was clearly observed in the retina at P8. A weak band of 150 kDa corresponding to the core protein of the C-terminal processing product was also detected (Fig. 5G). At P60, only a very weak core protein band of 150 kDa was noted.
RCS Rats. At P8, no differences were noted compared with normal retinas. At P60, however, a weak band of 250 kDa and a strong band of 150 kDa were observed (Fig. 5G). This latter form was even evident without chondroitinase ABC treatment, appearing as a smear between 150 and 250 kDa, which disappeared after the treatment.

**DISCUSSION**

**Normal Rats**

A strong band of 250 kDa, likely to be equivalent to the 220-kDa band observed by Inatani et al.\(^{13}\) and a weaker band of 150 kDa were seen after chondroitinase ABC treatment of P8 retinal homogenates, in contrast to their report, in which the 150-kDa band became the dominant form at this early age. However, the monoclonal antibody that they used is likely to detect only one epitope in both neurocan forms, whereas the antiserum used in the present study also detects epitopes in N-terminal regions not present in the 150-kDa form.

The distribution of neurocan during postnatal rat retinal development in our study otherwise agrees to a great extent with the observations made by Inatani et al.\(^{15}\) Transient expression was observed in the retina in areas of fiber outgrowth, which supports the notion that neurocan plays a role also in
the retina in directing dendritic and axonal outgrowth.\textsuperscript{46,47} Immunoreactivity was seen also pericellularly in the developing neuroblastic layer and in the ganglion cell layer. At P5, accumulation of labeling was observed in patches within the INL that appeared to delineate two levels of differentiation within this layer. In addition, a number of immunolabeled radial profiles were observed in the developing INL that, as suggested by Inatani et al.,\textsuperscript{13} seemed to correspond to accumulation in or in association with Müller cell processes. Such labeling was observed only during the first two postnatal weeks, suggesting that neurocan could also participate as a regulator of cell migration in the developing retina.

In adult retinas, neurocan immunolabeling was detected in the subretinal space. The same distribution has not been observed previously\textsuperscript{13} and may be due to differences in the processing of the tissue sections. It is possible that the shorter fixation protocol used in the present study favored the detection of labeling in the outer retina. In addition, the polyclonal antiserum used in this study also detects, as mentioned earlier, the hyaluronan-binding N-terminal part of the molecule. Hyaloton binding.
luronic and proteoglycans have been shown to be among the major constituents of the interphotoreceptor matrix (IPM) in rodents and in other species and have been suggested to play a role, for instance, in adhesion of the retinal pigment epithelium. Further, the matrix metalloproteinase (MMP)-2, identified as a protease likely to process neurocan, is present in the IPM, further suggesting that neurocan is a component of the IPM. The onset of accumulation of neurocan in the IPM in the present study coincides with the appearance of outer segments at P5, suggesting that neurocan could be involved in photoreceptor outer segment development and/or maintenance.

Weak neurocan immunolabeling was also observed in adult rats retina or the NFL. It was not possible to determine unequivocally which neurocan form is present at this time point, but MMP-2 has been shown to be constitutively expressed in retinal ganglion cells and their axons, suggesting that in the retina a developmentally increasing fraction of neurocan may be proteolytically processed, as previously observed in brain tissue.

The distribution of neurocan in the retina in the present study confirms previous studies showing that its expression is developmentally regulated, and suggests also that neurocan may be involved in different processes in different parts of the retina. It should be noted, however, that no obvious morphologic defects have been observed in Nissl staining of brain sections or in hematoxylin-eosin-stained retinal sections (Perez M-TR, unpublished observations, 2001) from neurocan-null mice, whereas deficits in synaptic plasticity were observed in the hippocampus of these animals. These observations suggested some redundancy among lecticans or other proteoglycans in defining structure. However, they indicate also that neurocan plays a functional role (possibly also in the retina) at least in some processes, that cannot be fully compensated for by other molecules.

RCS, P23H, and S334ter Rats

In P23H and S334ter rats, the distribution of neurocan remained comparable to that of normal retinas, despite the progressive photoreceptor cell loss. In RCS rats however, an increased accumulation of neurocan was present throughout the photoreceptor outer segments. As mentioned earlier, the IPM is rich in glycoproteins and proteoglycans, and alterations in the levels and distribution of some of these molecules have been observed in RCS rats. The increased accumulation of neurocan in the subretinal space appeared to parallel the gradual build-up of undigested disc membranes, and at late stages neurocan was present even in areas where photoreceptors were lost and only a debris zone remained, suggesting that the accumulation may reflect mainly delayed degradation of neurocan rather than increased synthesis. This could explain why a similar subretinal accumulation of neurocan was not noted in P23H and S334ter rats, in which phagocytosis of shed outer segments appears to function normally.

In RCS rats, a conspicuous accumulation of neurocan was also present in association with the retinal vasculature. A similar accumulation of neurocan or of other members of the lectican family has not to our knowledge, been described previously. After a lesion of the entorhinal cortex in adult rats, for example, a strong upregulation of neurocan was observed in the fascia dentata, with no particular deposition around the basal lamina of blood vessels. However, our observations seem consistent with previously reported alterations in the...
composition of the extracellular matrix (ECM) and in the thickness of the matrix layer surrounding the retinal vessels in RCS rats. In these animals, the most severe vascular changes involve vascular contraction, vascularization of the RPE, vascular proliferation, and formation of vitreoretinal membranes, changes that are generally thought to be secondary to photoreceptor cell death.

However, actual pathologic loss of photoreceptors is believed to begin in RCS rats at around P20, and we found an accumulation of neurocan around central vessels as early as P15, suggesting that it does not occur, at least initially, as a result of the photoreceptor cell loss. On the other hand, an abnormal accumulation of disc membranous debris is noticeable in RCS rats at around P12, and alterations in the distribution of certain IPM components are present before the period of degenerative photoreceptor cell loss. The early accumulation of neurocan around vessels in RCS rats could thus be triggered by changes in the biochemical environment of the subretinal space as membranous discs start to accumulate. Müller cells, which span radially the entire thickness of the retina, could in this case convey signals and/or transport molecules from the subretinal space to the remainder of the retina. Degeneration of perivascular Müller cell processes has been reported in RCS rats, which, as suggested by Roque and Caldwell, could result in alterations in the ECM and thereby in alterations of endothelial cell function.

An abnormal accumulation of the MMP inhibitor, tissue inhibitor of metalloproteinase (TIMP)-3, has been observed in association with the retinal vasculature in human retinas with retinitis pigmentosa. Reduced proteolysis by TIMP-3 or other proteinase inhibitors could occur in RCS rat retinas, resulting in accumulation of various components of the perivascular matrix, including neurocan. With time, the accumulated neurocan could, in turn, modulate some of the subsequent events involving the vasculature. Vascularization of the RPE by retinal vessels occurs, for instance, in RCS rats in areas where photoreceptors and outer segment debris have disappeared. As shown previously and in the present study, RPE cells are present along retinal vessels and in the vitreous margin of the retina in RCS rat retinas. RPE-associated changes in the composition and thickness of the perivascular matrix have been suggested to modulate, at least in part, the migration and proliferation of retinal endothelial cells. An accumulation of neurocan was present around the vessels long before RPE cells were visible intraretinally. This indicates that migrated RPE cells are not, at least at the initial stages, the primary source of the accumulated neurocan. It is possible, however, that the neurocan accumulated perivascularly ultimately creates, through interactions with other matrix molecules, a substrate for the migration of the RPE cells. Versican, another hyaluronan-binding matrix proteoglycan, and decorin, which, along with versican, has been detected in the normal retina, have been suggested to play a role in proliferative diabetic retinopathy and in the formation of epiretinal membranes in proliferative vitreoretinopathy.

In contrast to the situation observed in normal retinas, neurocan was clearly detected by immunoblot analysis in adult RCS rats. The predominant 150-kDa band conformed with the proteolytic state normally observed in brain at this age. It could also point to a glial origin, given that an increased astrocytic expression of neurocan occurs after neuronal injury, and that cleavage of neurocan can occur intracellularly in astrocytes, possibly by the protease MMP-2, which has been found to be expressed in these cells. Accumulation of neurocan was not observed in the Müller cells themselves in RCS rats; however, the possibility might be considered that these cells are somehow involved in the process of accumulation or are even a source of the accumulated neurocan.

It is not possible, however, to establish at this point what exactly triggers the accumulation of neurocan around vessels in RCS rats, which cell(s) may be involved, whether neurocan plays a role in the vasculature, or which role it plays. No neurocan labeling was detected in our study in association with normal retinal vascular development. Further, although some accumulation of neurocan was associated with vessels in P23H and S334ter rats, it was far less prominent than in RCS rats, and occurred long after photoreceptor cells started to die. Not much is yet known about vascular changes that occur in the mutant rhodopsin transgenic rats that we studied. However, vascular changes have been reported in several other animal models of photoreceptor cell degeneration and in human retinitis pigmentosa, and alterations of the perivascular matrix have also been observed in many of these cases.

The observations in the present study thus indicate that vessel-associated accumulation of neurocan can occur, but is not a general phenomenon or even a common feature of all types of photoreceptor cell degeneration. It appears instead that the particular conditions created in the subretinal space in RCS rats are what trigger the abnormal accumulation. Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, have also been identified in patients with degenerative retinal disease, and it is conceivable that similar vascular alterations occur in the retinas of these individuals. Neurocan and another CS-PG, phosphacan, have been shown to bind with high affinity to fibroblast growth factor (FGF)-2, an angiogenic factor. Increased levels of FGF-2 are noted in RCS rats. There is thus the possibility that binding of accumulated neurocan to this or other growth factors is directly or indirectly involved in some of the vascular changes observed in RCS rats and perhaps also in patients with MERTK mutations.

Acknowledgments

The authors thank Berndt Ehinger and Reinhard Fassler (Lund University) for support, Olaf Strauss (Freie University, Berlin, Germany) for providing the RCS-rdy rats with nondystrophic retinas, and Karin Arnér and Gunnel Roos for technical assistance.

References


